Prevalence and Risk Factors for Persistent Post‐COVID‐19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID‐19 Study
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Miyuki Hori und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security, Tokyo, Shinjuku-ku, Japan. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MHLW Research on Emerging and Re-Emerging Infectious Diseases and Immunization.
Abstract (Originalsprache)
The risk factors for long‐term persistent post‐coronavirus disease (COVID‐19) condition (PCC) years after infection remain unclear. In this study, we investigated the prevalence of PCC and the associated risk factors after severe acute respiratory syndrome coronavirus 2 infection in the general population. This prospective cohort study included individuals aged 18–79 years diagnosed with COVID‐19 between March 2021 and April 2022 and matched non‐infected individuals living in Yao City, Japan. Baseline and follow‐up surveys were conducted in 2022 and 2024, respectively. PCC was defined as symptoms persisting for ≥2 months at 3 months post‐infection. Among 7404 eligible individuals, 3628 (2314 infected, mean age: 44.2 years, 62.7% females; 1314 non‐infected, mean age: 45.0 years, 63.2% females) participated in the follow‐up survey. PCC prevalence at 3, 6, 12, and 18 months was 14.3%, 12.0%, 6.3%, and 5.4%, respectively. Older age, being overweight, comorbidities, severe disease in the acute phase, and low household income were associated with persistent PCC at ≥ 18 months. Compared with no vaccination, ≥ 2 doses of the COVID‐19 vaccine prior to infection were associated with a lower PCC risk. These findings highlight PCC as an important public health concern in the post‐COVID‐19 era. Trial Registration: UMIN000049807
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Global Health Policy Research, Bureau of Global Health Cooperation, Japan Institute for Health Security, Tokyo, Shinjuku-ku, Japan.
- Yao City Public Health Center, Osaka, Yao, Japan.
- Health and Environmental Risk Division, National Institute for Environmental Studies, Ibaraki, Japan.
ORCID-Profile: Miyuki Hori, Mariko Hosozawa, Yoko Muto
Förderung
- MHLW Research on Emerging and Re-Emerging Infectious Diseases and Immunization
Zitieren
APA
Hori, M., Hayama-Terada, M., Kitamura, A., Hosozawa, M., Muto, Y., Iba, A., Takayama, Y., Kimura, T., & Iso, H. (2026). Prevalence and Risk Factors for Persistent Post‐COVID‐19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID‐19 Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70973
Vancouver
Hori M, Hayama-Terada M, Kitamura A, Hosozawa M, Muto Y, Iba A, et al. Prevalence and Risk Factors for Persistent Post‐COVID‐19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID‐19 Study. Journal of Medical Virology. 2026. doi:10.1002/jmv.70973
BibTeX
@article{Hori2026,
author = {Hori, Miyuki and Hayama-Terada, Mina and Kitamura, Akihiko and Hosozawa, Mariko and Muto, Yoko and Iba, Arisa and Takayama, Yoshihiro and Kimura, Takashi and Iso, Hiroyasu},
title = {Prevalence and Risk Factors for Persistent Post‐COVID‐19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID‐19 Study},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70973}
}
EUVIMED